Seocalcitol

Drug Profile

Seocalcitol

Alternative Names: CB-1089; EB-1089

Latest Information Update: 10 Dec 2015

Price : $50

At a glance

  • Originator LEO Pharma
  • Developer Cougar Biotechnology; LEO Pharma
  • Class Antineoplastics; Vitamin D analogues
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 29 Mar 2010 Phase-I development is ongoing in USA
  • 10 Jul 2009 Cougar Biotechnology has been acquired by Johnson and Johnson
  • 07 May 2007 Phase-I clinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top